Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chad E Stephens

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Plos One|August 5, 2011
Combined treatment of heterocyclic analogues and benznidazole upon Trypanosoma cruzi in vivoDenise da Gama Jaén Batista, Marcos Meuser Batista, Gabriel Melo de Oliveira, et al.
Journal of Molecular Biology|August 18, 2010
DNA minor groove induced dimerization of heterocyclic cations: compound structure, binding affinity, and specificity for a TTAA siteManoj Munde, Arvind Kumar, Raja Nhili, et al.
Journal of Pharmaceutical Sciences|November 5, 2013
CYP1A1 and CYP1B1-mediated biotransformation of the antitrypanosomal methamidoxime prodrug DB844 forms novel metabolites through intramolecular rearrangementWujian Ju, Sihyung Yang, John H Ansede, et al.
Experimental Parasitology|June 13, 2009
Trypanosoma cruzi: activity of heterocyclic cationic molecules in vitroMichele Gabriele de Oliveira Pacheco, Cristiane França da Silva, Elen Mello de Souza, et al.
Nucleic Acids Research|October 25, 2012
Targeting the DNA-binding activity of the human ERG transcription factor using new heterocyclic dithiophene diamidinesRaja Nhili, Paul Peixoto, Sabine Depauw, et al.
Parasitology|September 10, 2011
The efficacy of novel arylimidamides against Trypanosoma cruzi in vitroCristiane França DA Silva, Anissa Daliry, Patrícia Bernardino DA Silva, et al.
Drug Design, Development and Therapy|April 25, 2017
Phenotypic evaluation and in silico ADMET properties of novel arylimidamides in acute mouse models of <i>Trypanosoma cruzi</i> infectionCristiane França da Silva, Denise da Gama Jaén Batista, Julianna Siciliano de Araújo, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 26, 2006
CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime]Michael Zhuo Wang, Janelle Y Saulter, Etsuko Usuki, et al.
Antimicrobial Agents and Chemotherapy|May 12, 2010
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatmentDenise da Gama Jaén Batista, Marcos Meuser Batista, Gabriel Melo de Oliveira, et al.
Antimicrobial Agents and Chemotherapy|April 7, 2010
Novel arylimidamides for treatment of visceral leishmaniasisMichael Zhuo Wang, Xiaohua Zhu, Anuradha Srivastava, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Plos One|August 5, 2011
Combined treatment of heterocyclic analogues and benznidazole upon Trypanosoma cruzi in vivoDenise da Gama Jaén Batista, Marcos Meuser Batista, Gabriel Melo de Oliveira, et al.
Journal of Molecular Biology|August 18, 2010
DNA minor groove induced dimerization of heterocyclic cations: compound structure, binding affinity, and specificity for a TTAA siteManoj Munde, Arvind Kumar, Raja Nhili, et al.
Journal of Pharmaceutical Sciences|November 5, 2013
CYP1A1 and CYP1B1-mediated biotransformation of the antitrypanosomal methamidoxime prodrug DB844 forms novel metabolites through intramolecular rearrangementWujian Ju, Sihyung Yang, John H Ansede, et al.
Experimental Parasitology|June 13, 2009
Trypanosoma cruzi: activity of heterocyclic cationic molecules in vitroMichele Gabriele de Oliveira Pacheco, Cristiane França da Silva, Elen Mello de Souza, et al.
Nucleic Acids Research|October 25, 2012
Targeting the DNA-binding activity of the human ERG transcription factor using new heterocyclic dithiophene diamidinesRaja Nhili, Paul Peixoto, Sabine Depauw, et al.
Parasitology|September 10, 2011
The efficacy of novel arylimidamides against Trypanosoma cruzi in vitroCristiane França DA Silva, Anissa Daliry, Patrícia Bernardino DA Silva, et al.
Drug Design, Development and Therapy|April 25, 2017
Phenotypic evaluation and in silico ADMET properties of novel arylimidamides in acute mouse models of <i>Trypanosoma cruzi</i> infectionCristiane França da Silva, Denise da Gama Jaén Batista, Julianna Siciliano de Araújo, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 26, 2006
CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime]Michael Zhuo Wang, Janelle Y Saulter, Etsuko Usuki, et al.
Antimicrobial Agents and Chemotherapy|May 12, 2010
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatmentDenise da Gama Jaén Batista, Marcos Meuser Batista, Gabriel Melo de Oliveira, et al.
Antimicrobial Agents and Chemotherapy|April 7, 2010
Novel arylimidamides for treatment of visceral leishmaniasisMichael Zhuo Wang, Xiaohua Zhu, Anuradha Srivastava, et al.
Pageof 5